Phenylephrine and Noradrenaline for Post Spinal Anesthesia Hypotension

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: spinalhypotensiontermcesareanpost
  Phrases that lowered it: the effecteffect ofbleedingmass indexbody mass
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: 13.9% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 65.9% (lowers risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 22 (lowers risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 31884 (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 137033 (lowers risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Maximum age: 35 (lowers risk) · Who can join
• Number of arms: 2 (raises risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Comparison of Phenylephrine and Norepinephrine for Spinal-induced Hypotension NCT04789005 · started 2019 · scored riskier than 7% of active trials completed
• Norepinephrine or Phenylephrine in Bolus for Hypotension in Cesarean Delivery NCT03702400 · started 2018 · scored riskier than 5% of active trials completed
• Comparative Analytical Study of Intravenous Bolus Dose of Mephentermine and Phenylephrine for Hemodynamic Stability During Elective Cesarean Section Under Spinal Anesthesia at KIST Medical College and Teaching Hospital NCT05706727 · started 2023 · scored riskier than 6% of active trials completed
• Phenylephrine and Hypotension During Spinal Anesthesia for Cesarean Section NCT02958215 · started 2016 · scored riskier than 8% of active trials completed
• Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section NCT07480889 · started 2026 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.